期刊文献+

FADD在喉癌的表达及临床意义 被引量:3

Expression and clinical significance of FADD in carcinoma of larynx
下载PDF
导出
摘要 【目的】探讨FADD在喉癌组织中的表达情况及其与临床的关系。【方法】应用免疫组织化学方法检测30例喉鳞状细胞癌组织、20例喉乳头状瘤组织、20例癌旁正常粘膜组织中FADD的表达情况。【结果】(1)FADD在喉鳞状细胞癌组、喉乳头状瘤组及癌旁正常粘膜组中的阳性表达率分别为76.7%、90.0%、95.0%,阳性表达率总体有统计学意义(P<0.05)。(2)FADD的阳性表达率在喉癌I^II期的阳性表达率为95.2%,III^IV期为50.0%,有统计学意义(P<0.05);在高分化癌组织中的阳性表达率为94.4%,中低分化癌组织中的阳性表达率为25.0%,有统计学意义(P<0.05)。FADD阳性表达率与患者性别、年龄、不同临床分型及是否伴有淋巴结转移均无关,无统计学意义(P>0.05)。【结论】FADD在喉癌的发生发展中起着重要的作用,癌组织中FADD的检测对临床预后的判断有一定的指导意义。 【Objective】To explore the clinical significance of FADD in laryngeal squamous carcinoma.【Methods】 The expression of FADD were detected by immunohistochemiscal(IHC) method in 30 cases of larynx squamous cell carcinoma(LSCC),20 cases of papilloma of larynx and 20 cases of normal adjacent mucosa.【Results】(1) The positive expression rate of FADD in LSCC group,papilloma of larynx group and normal adjacent mucosa group were 76.7%,90.0%,95.0% respectively,the positive expression rate have statistical significance in total(P0.05).(2) The positive expression rates of FADD were related to cinical stage and with the degree of pathological differentiation,that.In stage I-II group of LSCC was 95.2% and stage of III-IV was 50.0%,with statistical significance(P0.05).In LSCC of high differentiation was 94.4%,higher than middle-poorly differentiated(25.0%),with statistical significance(P0.05).But no relation to sexuality,age,clinical classification and the lymph node metastasis.There were have no statistical significance(P0.05).【Conclusions】 FADD plays an important role in the occurrence and development of carcinoma of larynx.Determination expression rate of FADD may provide guidance for clinical prognosis.
出处 《武警医学院学报》 CAS 2010年第10期761-763,F0002,共4页 Acta Academiae Medicinae CPAPF
基金 武警医学院科研基金项目(WY2008-19)
关键词 喉鳞状细胞癌 FADD 免疫组织化学 Larynx squamous cell carcinoma Fas-associated death domain protein Imunohistochemistry
  • 相关文献

参考文献8

二级参考文献21

  • 1刘志能,唐良萏.cFLIP与卵巢癌[J].重庆医学,2005,34(10):1554-1556. 被引量:7
  • 2刘志能,唐良萏.cFLIP与人类疾病[J].重庆医学,2006,35(1):78-81. 被引量:2
  • 3朱世能 从文铭.肝脏肿瘤病理学类型[A].刘复生.中国肿瘤病理学分类[C].北京:科学技术文献出版社,2001..
  • 4周文光,徐灵,李宝明,薛燕,周玫,程向荣.喉部分切除术治疗喉癌51例报告[J].实用癌症杂志,1997,12(1):36-37. 被引量:3
  • 5Chinnaiyan AM, O' Rourke K,Tewari M,et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 1995,81:505-512.
  • 6Strasser A,Newton K. FADD/MORT1 ,a signal transducer that can promote cell death or cell growth. Int J Biochem Cell Biol, 1999,31:533-537.
  • 7Trauzold A, Schmiedel S, Roder C, et al.Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer, 2003,89: 1715-1721.
  • 8Tourneur L, Mistou S, Michiels FM, et al.Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene, 2003,22:2795-2804.
  • 9Mishima K,Nariai Y,Yoshimura Y. Carboplatin induces Fas-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression. Iht J Cancer,2003,105:593-600.
  • 10Irmler M,Thome M,Hahne M,et al.Inhibition of death receptor signals by cellular FLIP[J].Nature,1997;388(6638):190-195.

共引文献22

同被引文献39

  • 1郭洪亮,赵红伟.结直肠癌预防研究进展[J].肿瘤学杂志,2006,12(3):180-183. 被引量:4
  • 2刘志能,唐良萏.cFLIP、FADD在宫颈癌组织中的表达及意义[J].重庆医科大学学报,2007,32(1):22-26. 被引量:4
  • 3Jaiswal s, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis[J]. Cell, 2009, 138(2): 271-285.
  • 4Pettersen RD, Hestdal K, Olafsen MK, et al. CD47 signals T cell death[J]. J Immunol, 1999, 162(12): 7031-7040.
  • 5Carani L, Sollazzo D, Ricci F, et al. The CD47 pathway is deregulated in human immune thrombocytopenia[J]. Exp Hematol, 2011, 39(4): 486-494.
  • 6Olsson M, Nilsson A, Oldenborg PA. Target cell CD47 regulates macrophage activation and erythrophagocytosis[J]. Transfus Clin Biol, 2006, 13(1-2): 39-43.
  • 7Chan KS, Volkmer JP, Weissman I. Cancer stem cells in bladder cancer: a revisited and evolving concept[J]. Curr Opin Urol, 2010, 20(5): 393-397.
  • 8Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma [ J]. Cell, 2010, 142(5): 699-713.
  • 9Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors[J]. Proc Natl Acad Sci USA, 2012, 109(17): 6662-6667.
  • 10Oldenborg PA, Gresham HD, Chen Y, et al. Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice[J]. Blood, 2009, 99(12): 3500-3504.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部